Peptide-MHC complexes presenting WT1, PRAME, and Survivin (BIRC5) tumor-associated antigen epitopes (WT1/PRAME/Survivin pMHC)

This target refers to the specific complexes formed by peptides derived from Wilms Tumor 1 (WT1), Preferentially Expressed Antigen in Melanoma (PRAME), and Survivin (BIRC5) when presented by Major Histocompatibility Complex (MHC) molecules on the surface of tumor cells [2, 12]. These three proteins are classified as tumor-associated antigens (TAAs) because they are overexpressed in a wide range of cancers—including acute myeloid leukemia (AML), lymphomas, and various solid tumors—while maintaining very low or absent expression in most healthy adult tissues [1, 15]. Targeting these pMHC complexes allows the immune system to identify and eliminate malignant cells that would otherwise be indistinguishable from healthy cells [4, 16]. Therapeutic approaches, such as MultiTAA T-cell therapies (e.g., MT-401) and T-cell receptor (TCR) mimic antibodies (e.g., Pr20), are designed to recognize these specific epitopes to induce a potent and selective anti-tumor immune response [8, 17]. By targeting multiple antigens simultaneously, these therapies aim to prevent tumor escape caused by the loss of a single antigen, a common challenge in monovalent immunotherapies [11, 13].

Other names

WT1/PRAME/Survivin-specific CTL targetsMulti-TAA pMHC complexesLeukemia-associated antigen complexesWT1/PRAME/BIRC5 epitopes

Adoptive T-cell therapy involving the infusion of T cells primed to recognize specific TAA epitopes presented on MHC, leading to direct cytolysis of tumor cells and potential epitope spreading.